Clinical Trials Logo

Idiopathic Parkinson's Disease clinical trials

View clinical trials related to Idiopathic Parkinson's Disease.

Filter by:

NCT ID: NCT00239564 Completed - Clinical trials for Idiopathic Parkinson's Disease

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release tablets.

NCT ID: NCT00148369 Completed - Clinical trials for Idiopathic Parkinson's Disease

A Multi-Center, Observational Safety Registry of Subjects With Idiopathic Parkinson's Disease Previously Treated With Intraputaminal Infusion of Liatermin

Start date: June 2005
Phase: N/A
Study type: Observational

The primary purpose of this study is to evaluate clinical and serologic outcomes after the discontinuation of liatermin therapy as assessed by development of new clinical conditions beyond those expected in patients with advancing Parkinson's disease. In addition, the development or resolution of anti-r-metHuGDNF binding and neutralizing antibodies will be monitored.

NCT ID: NCT00125567 Completed - Clinical trials for Idiopathic Parkinson's Disease

Stalevo in Early Wearing-Off Patients

SEWOP
Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.

NCT ID: NCT00115427 Completed - Clinical trials for Idiopathic Parkinson's Disease

Study of Liatermin (r-metHuGDNF) Administered by Bilateral Intraputaminal (IPu) Infusion to Subjects With Idiopathic Parkinson's Disease

Start date: March 2003
Phase: Phase 1
Study type: Interventional

This randomized study was designed to evaluate the efficacy and safety of IPu-infused liatermin (15mg/putamen/day) compared with placebo in subjects with symptomatic, levodopa-response Parkinson's disease. This study consisted of a 90-day evaluation period followed by implantation of the IPu delivery system and then a 6-month double-blind treatment period.